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12-weeks lead-in period. Secondary outcomes were quality-of-life,
6-meter walking time, grip strength, forced vital capacity, sniff nasal
inspiratory pressure, threshold tracking of the median nerve, neurophys-
iological index (NI) and cortical excitabilitymeasurements. Regarding the
aimed recruitment rate the trial was unsuccessful, consequently it was
underpowered for the primary outcome evaluation, which was negative.Amyotrophic lateral sclerosis (ALS) is a dreadful degenerative disor-
generally negative, except for the NI that had a signiﬁcantly slower
decline in the treated than the placebo-arm (p = 0.02), this differenceder, characterized by rapidly progressing weakness causing respiratory
impairment and death, in spite of moderate beneﬁts from non-invasive
ventilation, gastrostomy, riluzole treatment and multidisciplinary care
(Andersen et al., 2012). Over the years a large of number of drugs
have been tested to deal with this disorder, but all trials have been neg-
ative except for riluzole. We can observe that different strategies have
been explored in the past, from immunosuppression to neuroprotec-
tion, from nerve growth factors to antiglutamatergic compounds (de
Carvalho et al., 2005). Threshold tracking has been used to investigate
axonal excitability in peripheral nerve motor axons in ALS (Vucic and
Kiernan, 2006). Increased persistent Na+ conductance and reduced
K+ conductance have been described (Vucic and Kiernan, 2006),
which tend to become more marked with disease duration and
may be a predictor of survival (Cheah et al., 2012). More recently,
it has been suggested that motor neurons have an abnormal func-
tion of the membrane ion channels, in ALS (Devlin et al., 2015).
These observations have opened a new window of opportunity in
clinical trials for ALS, for testing drugs that modulate ion channels
in order to stabilize membranes.
In this issue of EBioMedicine, Park et al. reported the ﬁrst trial of
ﬂecainide (200 mg/day for 32 weeks) in ALS (Park et al., 2015). This
drug is a class Ic antiarrhythmic agent that was synthesized in 1972,
its clinical efﬁcacy has been conﬁrmed in the past, currently mostly
used to in the management of atrial ﬁbrillation and supraventricular
tachycardia. Flecainide is a blocker of the persistent sodium current,
then promoting membrane stabilization. Although this drug has not
been tested in the animal model of ALS, the authors decided to test
it in a group of 54 ALS patients, following a randomized, placebo-
controlled, double-blind design. Primary outcome was the rate ofom.2015.11.022.
aria, Av. Professor Egas Moniz,
. This is an open access article underImportantly, the drug was well tolerated. The secondary outcomes were
was not observed when comparing the same two groups during the
lead-in period. It should be stressed that peripheral excitability remained
stable after ﬂecainide treatment, but in the placebo group it was observed
a reduction of the hyperpolarizing threshold electrotonus.
Although thismay be considered a negative trial by simply regarding
the primary outcome assessment, it is interesting to observe that NI de-
clined less in the active-arm.NI is a simple, reproducible and easily stan-
dardizedmeasurement of the lowermotor neuron pool, which declines
faster than ALSFRS and motor response amplitude (de Carvalho and
Swash, 2006). Its behavior over disease progression makes appropriate
to use linearmixedmodels to evaluate its change in clinical trials for ALS
(Cheah et al., 2011). Indeed, this outcome was used in another clinical
trial before (de Carvalho et al., 2010). Threshold tracking to test excit-
ability of the peripheral axon was not used before in clinical trials, but
it is a very suitable technique to evaluate drugs that could act on the
ion channels to promote neuroprotection in ALS. In this trial, the pro-
gressively increased hyperpolarization observed in the control arm
was not disclosed in the group of patients taking the drug, suggesting
membrane stabilization, which is a meaningful result (Park et al.,
2015). Furthermore, such membrane stabilization and reduction in ex-
citability did not exert a deleterious effect on ALS patients, opening up
the landscape for future trials in this area.
These results have a number of implications for future studies.
More trials are recommended with drugs acting as membrane stabi-
lizers, currently the antiepileptic drug retigabine (a potassium chan-
nel opener) is being tested (https://clinicaltrials.gov/ct2/show/
NCT02450552, n.d.); ﬂecainide should be further investigated in a
larger trial; a number of safe drugs that are available for other clin-
ical conditions should be considered as targets for clinical trials in
ALS, since their properties are relevant for this disorder; NI should
be applied in future trials as a measurement of the lower motor neu-
ron degeneration; a lead-in period to select homogenous group of
ALS patients could increase the chances of ﬁnding positive results
(de Carvalho and Swash, 2006).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1843M. de Carvalho / EBioMedicine 2 (2015) 1842–1843Our increasing knowledge of both drugs and the biology of ALS has
resulted in new treatment strategies. The most promising approach is
to develop compounds acting on the pathogenic process, since causal
treatment is a more demanding alternative that will require more
time to be fruitful. Although other pathogenic pathways areworthwhile
to be considered, as RNA dysmetabolism, autophagy impairment, neu-
roinﬂammation, glutamatergic excitoxicity and axonal transport distur-
bance, the possibility to stabilize motor neuron and axonal membranes
is an exciting new avenue that deserves more intensive work.
Disclosure
The author declared no conﬂicts of interest.
References
Andersen, P., Abrahams, S., Borasio, G.D., de Carvalho, M., Chio, A., Damme, V., et al., 2012.
EFNS guidelines on the clinical management of amyotrophic lateral sclerosis
(MALS)—revised report of an EFNS task force. Eur. J. Neurol. 19, 360–375.Cheah, B.C., Vucic, S., Krishnan, A.V., Boland, R.A., Kiernan, M.C., 2011. Neurophysiological
index as a biomarker for ALS progression: validity of mixed effects models.
Amyotroph. Lateral Scler. 12, 33–38.
Cheah, B.C., Lin, C.S., Park, S.B., Vucic, S., Krishnan, A.V., Kiernan, M.C., 2012. Progressive
axonal dysfunction in clinical impairment in amyotrophic lateral sclerosis. Clin.
Neurophysiol. 123, 2460–2467.
de Carvalho, M., Swash, M., 2006. Can selection of rapidly progressing patients shorten
clinical trials in amyotrophic lateral sclerosis? Arch. Neurol. 63, 557–560.
de Carvalho, M., Costa, J., Swash,M., 2005. Clinical trials in ALS: a review of the role of clin-
ical and neurophysiological measurements. Amyotroph. Lateral Scler. 4, 202–212.
de Carvalho, M., Pinto, P., Costa, J., Evangelista, T., Ohana, B., Pinto, A., 2010. A randomized,
placebo-controlled trial of memantine for functional disability in amyotrophic lateral
sclerosis. Amyotroph. Lateral Scler. 11, 456–460.
Devlin, A.-C., Burr, K., Borooah, S., Joshua, D.F., Cleary, E.M., Geti, I., et al., 2015. Human
iPSC-derivedmotoneurons harbouring TARDP or C9orf72 ALS mutations are dysfunc-
tional despite maintaining viability. Nat. Commun. 12, 5999.
https://clinicaltrials.gov/ct2/show/NCT02450552
Park, S.B., Vucic, S., Cheah, B.C., Lin, C., Kirby, A., Mann, K., 2015. Flecainide in amyotrophic
lateral sclerosis as a neuroprotective strategy (fans): a randomized placebo-
controlled trial. EBioMedicine 12 (2), 1916–1922.
Vucic, S., Kiernan, M.C., 2006. Axonal excitability properties in amyotrophic lateral sclerosis.
Clin. Neurophysiol. 117, 1458–1466.
